血清 miR-194 下调预示着骨肉瘤患者预后不良。

Downregulation of serum miR-194 predicts poor prognosis in osteosarcoma patients.

机构信息

Department of Orthopedics, Daping Hospital, Army Medical University, Chongqing 400010, China.

出版信息

Ann Diagn Pathol. 2020 Jun;46:151488. doi: 10.1016/j.anndiagpath.2020.151488. Epub 2020 Mar 3.

DOI:10.1016/j.anndiagpath.2020.151488

PMID:32172218

Abstract

BACKGROUND

Circulating microRNAs (miRNAs) have promising potential as diagnostic and prognostic biomarkers for osteosarcoma. This study aimed to explore the expression pattern of serum miR-194 and its potential clinical value in patients with osteosarcoma.

METHODS

Messenger RNA was isolated from serum sample from 124 osteosarcoma patients, 60 periostitis patients and 60 healthy volunteers. The serum miR-194 level was then examined by quantitative real-time polymerase chain reaction (qRT-PCR). The bioinformatic analysis of the downstream targets of miR-194 was also performed.

RESULTS

The results showed serum miR-194 levels were significantly decreased in osteosarcoma patients compared to those in periostitis patients or healthy controls. Receiver-operating characteristic (ROC) analysis demonstrated that serum miR-194 had a good diagnostic value for identifying osteosarcoma subjects from periostitis patients and normal controls. In addition, serum miR-194 levels were dramatically increased following surgery in osteosarcoma cases. Moreover, low serum miR-194 expression was strongly correlated with positive metastasis and advanced clinical stage, as well as worse survival. Furthermore, serum miR-194 was confirmed to be an independent prognostic biomarker for osteosarcoma. Bioinformatic analysis showed that the downstream targeted genes of miR-194 were closely associated with cancer initiation and development.

CONCLUSION

In conclusion, our results have demonstrated that serum miR-194 might serve as a novel and promising biomarker for the detection and prognosis of osteosarcoma.

摘要

背景

循环 microRNAs（miRNAs）作为骨肉瘤的诊断和预后生物标志物具有很大的潜力。本研究旨在探讨血清 miR-194 的表达模式及其在骨肉瘤患者中的潜在临床价值。

方法

从 124 例骨肉瘤患者、60 例骨膜炎患者和 60 例健康志愿者的血清样本中分离信使 RNA，然后通过实时定量聚合酶链反应（qRT-PCR）检测血清 miR-194 水平。还对 miR-194 的下游靶标的生物信息学分析进行了研究。

结果

结果表明，与骨膜炎患者或健康对照者相比，骨肉瘤患者血清 miR-194 水平显著降低。受试者工作特征（ROC）分析表明，血清 miR-194 对鉴别骨肉瘤患者与骨膜炎患者和正常对照者具有良好的诊断价值。此外，骨肉瘤患者手术后血清 miR-194 水平显著升高。此外，低血清 miR-194 表达与阳性转移和晚期临床分期以及较差的生存密切相关。此外，血清 miR-194 被证实是骨肉瘤的一个独立预后生物标志物。生物信息学分析表明，miR-194 的下游靶基因与癌症的发生和发展密切相关。